Literature DB >> 548940

Serum and sputum levels of cefaclor.

C Simon, U Gatzemeier.   

Abstract

In a cross-over study, 10 healthy adult volunteers received 1 g cefaclor and 1 g cephalexin orally 1 hour after a standard breakfast. Serum levels of cefaclor rose somewhat faster and were higher than those of cephalexin in the first 60 minutes. At the end of the second hour the serum concentration of cephalexin was 50--100% higher. The area under the serum level curve averaged 45 hr-micrograms/ml for cefaclor and 60 hr-micrograms/ml for cephalexin. Calculated pharmacokinetic constants indicate that the absorption rate of cefaclor was nearly the same as that of cephalexin. The serum half-life of cefaclor was 1 hr. The urine recovery of cefaclor for 9 hours averaged 65%, whereas cephalexin resulted in a urine recovery of 85%. To evaluate sputum levels, 15 adult patients with bronchial carcinoma and secondary bronchitis or pneumonia were treated with 0.5 g of cefaclor orally 4 times daily. The mean individual sputum levels were 0.44 micrograms/ml (after the first dose) and 0.54 micrograms/ml (after repeated administration). In 10 other patients, after a single 1 g dose of cefaclor mean sputum levels after 1 hour and 3 hours doubled, whereas peak concentrations in sputum after 2 hours did not differ significantly. These results suggest that cefaclor will be useful in respiratory tract infections caused by sensitive bacteria.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 548940

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  [Assay of cefaclor in serum and urine (including stability test) using high pressure liquid chromatography (author's transl)].

Authors:  E Harhausen; C Simon
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa.

Authors:  D Honeybourne; J M Andrews; J P Ashby; R Lodwick; R Wise
Journal:  Thorax       Date:  1988-09       Impact factor: 9.139

3.  Branhamella catarrhalis respiratory infections in The Netherlands.

Authors:  F P Maesen; B I Davies
Journal:  Drugs       Date:  1986       Impact factor: 9.546

4.  Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice.

Authors:  N C Karalus; J E Garrett; S D Lang; R A Leng; G N Kostalas; R T Cursons; B C Cooper; C J Ryan
Journal:  Infection       Date:  1995       Impact factor: 3.553

5.  [Experience with cefaclor in the treatment of ear, nose and throat infections. Indications for cefaclor therapy (author's transl)].

Authors:  P Federspil; R Bach; C Weich; H J Wilhelm; E Tiesler; W Schätzle
Journal:  Infection       Date:  1979       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.